Phase III Double-Blind Trial Comparing Stereotactic Ablative Radiotherapy and Palliative Radiotherapy for Treating Oligoprogressive Metastatic Cancer

What this Trial Is About

Researchers are evaluating treatments for adults with oligoprogressive metastatic cancers, which means cancer that has spread but is limited to a few progressing sites. This phase III trial compares stereotactic ablative radiotherapy SABR with palliative conventional radiotherapy to see how they affect progression-free survival on the next systemic therapy, cancer outcomes, and quality of life. The study also aims to test the feasibility of enrolling participants and maintaining the studys double-blind design. Participants will be randomly assigned to one of two groups. The control group will receive a single dose of 8 Gy palliative radiotherapy to all progressing cancer sites. The experimental group will receive SABR, which delivers a high dose of precise radiotherapy to the targeted sites. Both groups may continue their current systemic cancer treatments or remain off systemic therapy depending on their situation. The treatments are given to manage up to five progressing lesions. During the study, participants will be monitored regularly for up to five years with scans and assessments at multiple time points. Researchers will evaluate progression-free survival, overall survival, treatment side effects, quality of life using questionnaires, and cost-effectiveness. The trial also tracks when participants start their next systemic therapy and where disease progresses. Safety and quality of life are carefully assessed throughout the study period.

Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers